摘要
目的:分析研究促性腺激素释放激素激动剂(GnRh-a)治疗卵巢子宫内膜异位症患者对血清激素、炎性因子及骨密度的影响。方法:选择2016年6月—2018年9月诊断为卵巢子宫内膜异位症患者86例,按随机数字表法分为对照组(43例)和观察组(43例),分别给予孕三烯酮和GnRh-a剂治疗。比较两组患者血清激素水平、炎性因子水平及骨密度。结果:观察组患者治疗后卵泡刺激素(FSH)、黄体生成素(LH)及肿瘤坏死因子(TNF)-α、白细胞介素(IL)-18、C反应蛋白(CRP)均低于对照组,差异有统计学意义(P<0.05);两组患者治疗后骨密度比较,差异无统计学意义(P>0.05)。结论:在子宫内膜异位症的治疗中,GnRh-a可以降低患者血清激素、炎症因子水平,并且未出现明显骨质流失,患者骨密度正常。
Objective:To study the effects of gonadotropin-releasing hormone agonist(GnRh-a)on serum hormones,inflammatory factors and bone mineral density in patients with ovarian endometriosis.Methods:All 86 patients with ovarian endometriosis diagnosed from June 2016 to September 2018 were selected as study samples.They were divided into control group(43 cases)and observation group(43 cases)according to random number table method.They were treated with progesterone and gonadotropin releasing hormone agonist respectively.The levels of serum hormones,inflammatory factors and bone mineral density were compared between the two groups.Results:The levels of follicule-stimulating hormone(FSH)and luteinizing hormone(LH)in the observation group were lower than those in the control group(P<0.05);the levels of tumor necrosis factor-α(TNF-α),interleukin-18(IL-18)and C-reactive protein(CRP)in the observation group were lower than those in the control group(P<0.05);there was no significant difference in bone mineral density between the two groups(P>0.05).Conclusion:In the treatment of endometriosis,gonadotropin releasing hormone agonists can reduce the levels of serum hormones and inflammatory factors in patients with endometriosis,and there is no obvious bone loss,and the patients'bone mineral density is normal.
作者
梅玉英
余咏梅
祝费隐
MEI Yuying;YU Yongmei;ZHU Feiyin(First Affiliated Hospital of Jiangxi Medical College,Shangrao 334300,China)
出处
《临床医药实践》
2019年第10期725-728,共4页
Proceeding of Clinical Medicine
基金
江西省上饶市科技计划项目(项目编号:20182CKJ04).
